Sumatriptan Succinate Injection
Product Images NDC 55111-693

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 55111-693). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Autoinjector (Autoinjector)

Sumatriptan Injection USP is a medication provided in a 6 mg/0.5 mL AUTOINJECTOR SYSTEM. The 15-injected-dose autoinjector is for subcutaneous injection only. The instruction to use the injector is provided in the text. The autoinjector is filled with a solution having 8 mg of sumatriptan succinate. The solution is sterile and pyrogenic and contains 3.5 mg of sodium chloride in 0 mL of the solution. The autoinjector should be stored between 15°C to 30°C. The manufacturer is Dr. Reddy's Laboratories Ltd in India.*

FDA Label Image

Carton (Carton)

This is a set of instructions on how to use the Sumatriptan autoinjector system for a patient. The text describes step-by-step how to properly use the pen and inject the medication under the skin. The product comes with two autoinjectors containing 6mg of Sumatriptan injection, prescribing information, and instructions for use. There is additional information and details available at eyecom/products or Sumatriptan bk. The text was not utilized for any valuable comprehensive use.*

FDA Label Image

Fig (Fig)

The text appears to be a diagram representing the estimated percentage of subjects with relief after taking placebo and Sumatriptan at different time intervals. The x-axis represents time in minutes and y-axis represents the percentage of subjects with relief. The estimated percentage of relief is indicated by the values 100%, 80%, 60%, and 10%. The diagram shows that Sumatriptan provides relief to a greater percentage of subjects compared to the placebo, starting at around 15 minutes after administration.*

FDA Label Image

Fig1 (Fig1)

FDA Label Image

Fig10 (Fig10)

FDA Label Image

Fig11 (Fig11)

FDA Label Image

Fig2 (Fig2)

FDA Label Image

Fig3 (Fig3)

FDA Label Image

Fig4 (Fig4)

FDA Label Image

Fig5 (Fig5)

FDA Label Image

Fig6 (Fig6)

FDA Label Image

Fig7 (Fig7)

FDA Label Image

Fig8 (Fig8)

FDA Label Image

Fig9 (Fig9)

FDA Label Image

Stru (Stru)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.